Samuel Hunter
Neurology · Spring Hill, TNNPI 1093808107
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $531,124 of the $675,534 with a category attached, or 78.6%. It is spread thinly across 38 manufacturers, the largest accounting for just 20.8%. Reporting peaked in 2019 at $273,719 and has fallen 99.6% since, to $1,022 in 2025. Among neurology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 896 payments — averaging $753.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$140K
- EMD Serono, Inc.$129K
- Biogen$84K
- Novartis$61K
- Johnson & Johnson$51K
- AstraZeneca$47K
- plus $164K from 32 others
Across 272 payments — averaging $8393.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$540K
- AbbVie$430K
- Bristol Myers Squibb$363K
- Novartis$186K
- Alkermes, Inc.$160K
- Janssen Research & Development, LLC$141K
- plus $463K from 6 others
What the payments were for
- Consulting fees$72,85011%
- Speaking & faculty fees$531,12479%
- Travel & lodging$53,0578%
- Food & beverage$17,8653%
- Education$6380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$675,534 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcrevusOcrelizumab | 16 | $630,508 |
| Kesimpta PenOfatumumab | 40 | $382,258 |
| FingolimodFingolimod Hcl | 50 | $311,272 |
| CopaxoneGlatiramer Acetate | 42 | $242,420 |
| VumerityDiroximel Fumarate | 20 | $189,602 |
| Teriflunomide | 77 | $184,072 |
| Dimethyl Fumarate | 70 | $162,122 |
| ZeposiaOzanimod Hydrochloride | 15 | $136,084 |
| MayzentSiponimod | 11 | $101,851 |
| Dalfampridine ErDalfampridine | 49 | $24,944 |
| Aimovig AutoinjectorErenumab-Aooe | 34 | $24,774 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $17,622 |
| Glatiramer Acetate | 12 | $17,458 |
| Emgality SyringeGalcanezumab-Gnlm | 16 | $13,088 |
| Oxcarbazepine | 81 | $6,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Ocrevus | $94 | $630,50816 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone, Acyclovir | $30 | $243,46587 claims |
| BiogenVumerity | $84,354 | $189,60220 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $15,995 | $136,08415 claims |
| NovartisMayzent | $61,030 | $101,85111 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $98 | $17,62212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 neurology providers in Tennessee.
Other neurology in Spring Hill
- Harold MosesNashville$438K
- Lucas ElijovichMemphis$415K
- David BrandesKnoxville$412K
- Sibyl WrayKnoxville$377K
- Christine HagenAlcoa$371K
- Mark LedouxMemphis$352K
- Christopher PendolaKingsport$344K
- Daniel ClaassenNashville$285K
- Khalid AlsherbiniMemphis$249K
- Andrei AlexandrovMemphis$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.